Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 32 Issue 6, June 2014

Illustration of diverse RNA hairpins (yellow and orange) binding to coat proteins (blue) inside an assembling MS2A viral capsid. Buenrostro et al. repurpose an Illumina sequencer (yielding raw black and white fluorescence images in background) for high-throughput measurement of RNA-protein binding affinities to study structure-function relationships (represented by the hexagonal RNA hairpin diagrams) (p 562). Credit: Carlos L. Araya

Editorial

  • Industry needs to fully embrace efforts by regulators to release clinical trial data on approved products, despite lingering concerns over the public release of confidential business information. It is simply the right thing to do.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Correction

Top of page ⤴

News

Top of page ⤴

Bioentrepreneur

Top of page ⤴

Commentary

Top of page ⤴

Correspondence

Top of page ⤴

Feature

  • Confidential business information is commonly used to hide data about industry products from public view. Researchers, regulators and companies are currently struggling to redefine who needs to know what about commercial products and when they need to know it.

    • Laura DeFrancesco
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Perspective

Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Erratum

Top of page ⤴

Corrigendum

Top of page ⤴

Erratum

Top of page ⤴

Corrigendum

Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Quick links